- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Andaris agent enters renal study
Ultrasound contrast developer Andaris is exploring radiological applications for its Quantison agent. The Nottingham, U.K.-based company has begun a phase II clinical trial to examine the efficiency of the intravenous agent during renal imaging. To be
Ultrasound contrast developer Andaris is exploring radiological applications for its Quantison agent. The Nottingham, U.K.-based company has begun a phase II clinical trial to examine the efficiency of the intravenous agent during renal imaging. To be conducted at the University Hospital Dijkzigt in Rotterdam, the Netherlands, the trial will employ Quantison during renal imaging in patients with hypertension resulting from renal artery stenosis that was proven angiographically.
Quantison, which consists of a 3-micron air-filled albumin microcapsule, was initially designed for myocardial perfusion and cardiac chamber analysis; previous clinical studies have showed good results in both left ventricular opacification and myocardial perfusion, according to the company. In February, company executives said that Quantison might also be suitable for peripheral vascular and general radiology applications (SCAN 2/5/97).
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
